Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N P Restifo

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Seminars in Cancer Biology|December 1, 1995
The next wave of recombinant and synthetic anticancer vaccinesK R Irvine, N P Restifo
Trends in Immunology|April 5, 2001
Creating therapeutic cancer vaccines: notes from the battlefieldW W Overwijk, N P Restifo
Current Opinion in Oncology|January 23, 1999
Developing recombinant and synthetic vaccines for the treatment of melanomaN P Restifo, S A Rosenberg
Current Protocols in Immunology|April 25, 2008
B16 as a mouse model for human melanomaW W Overwijk, N P Restifo
Cancer Immunology, Immunotherapy : CII|October 13, 1998
T cell-tumor cell: a fatal interaction?D B Chappell, N P Restifo
Vaccine|December 2, 1999
DNA and RNA-based vaccines: principles, progress and prospectsW W Leitner, H Ying, N P Restifo
The Cancer Journal From Scientific American|February 24, 2000
The future of interleukin-2: enhancing therapeutic anticancer vaccinesW W Overwijk, M R Theoret, N P Restifo
Gene Therapy|February 16, 2000
The promise of nucleic acid vaccinesN P Restifo, H Ying, L Hwang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 16, 1997
Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapyA Porgador, O Mandelboim, N P Restifo, et al.
Metabolism: Clinical and Experimental|January 1, 1991
The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in manP W Pisters, N P Restifo, E Cersosimo, et al.
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Seminars in Cancer Biology|December 1, 1995
The next wave of recombinant and synthetic anticancer vaccinesK R Irvine, N P Restifo
Trends in Immunology|April 5, 2001
Creating therapeutic cancer vaccines: notes from the battlefieldW W Overwijk, N P Restifo
Current Opinion in Oncology|January 23, 1999
Developing recombinant and synthetic vaccines for the treatment of melanomaN P Restifo, S A Rosenberg
Current Protocols in Immunology|April 25, 2008
B16 as a mouse model for human melanomaW W Overwijk, N P Restifo
Cancer Immunology, Immunotherapy : CII|October 13, 1998
T cell-tumor cell: a fatal interaction?D B Chappell, N P Restifo
Vaccine|December 2, 1999
DNA and RNA-based vaccines: principles, progress and prospectsW W Leitner, H Ying, N P Restifo
The Cancer Journal From Scientific American|February 24, 2000
The future of interleukin-2: enhancing therapeutic anticancer vaccinesW W Overwijk, M R Theoret, N P Restifo
Gene Therapy|February 16, 2000
The promise of nucleic acid vaccinesN P Restifo, H Ying, L Hwang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 16, 1997
Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapyA Porgador, O Mandelboim, N P Restifo, et al.
Metabolism: Clinical and Experimental|January 1, 1991
The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in manP W Pisters, N P Restifo, E Cersosimo, et al.
Pageof 10